Our analysis suggested that SESN3 may reduce T cell expression of CD3, a co-receptor essential for T cell activation and the target of teplizumab (a monoclonal antibody approved to delay the onset of stage 3 type 1 diabetes) [4], and CD28, a key activator of T cells. The gene discussed is CD28; the disease is type 1 diabetes mellitus.